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Hepatitis C virus (HCV) infects 200 million people globally, and 60-80% of cases persist as a chronic infection that will progress to cirrhosis and liver cancer in 2-10% of patients [1] [2] [3] . We recently demonstrated that HCV induces aberrant expression of two host microRNAs (miRNAs), miR-208b and miR-499a-5p, encoded by myosin genes in infected hepatocytes 4 . These miRNAs, along with AU-rich-element-mediated decay, suppress IFNL2 and IFNL3, members of the type III interferon (IFN) gene family, to support viral persistence. In this study, we show that miR-208b and miR-499a-5p also dampen type I IFN signaling in HCV-infected hepatocytes by directly down-regulating expression of the type I IFN receptor chain, IFNAR1. Inhibition of these miRNAs by using miRNA inhibitors during HCV infection increased expression of IFNAR1. Additionally, inhibition rescued the antiviral response to exogenous type I IFN, as measured by a marked increase in IFN-stimulated genes and a decrease in HCV load. Treatment of HCV-infected hepatocytes with type I IFN increased expression of myosins over HCV infection alone. Since these miRNAs can suppress type III IFN family members, these data collectively define a novel cross-regulation between type I and III IFNs during HCV infection.
HCV is a single-stranded hepatotropic RNA virus against which no vaccine currently exists. Previously, the standard of care for chronic HCV infection was combination treatment with pegylated IFN-α (pegIFN-α) and ribavirin, which produced a sustained virological response in fewer than 40% of patients 5 . With the addition of protease inhibitors, a type of direct-acting antiviral (DAA), to pegIFN-α and ribavirin therapy, viral cure rates have improved to 56-95% of patients; the exact rate is dependent on both virus and host factors [6] [7] [8] [9] . Following this success, therapeutic advancements have focused on interfering with the viral lifecycle, and many new DAA drugs are currently in clinical trials 6, 10 . More recently, interferon-free combinations of HCV protease and RNA polymerase inhibitors, sometimes with ribavirin, have produced dramatic results in a subset of patients 10 . However, the emergence of resistant HCV variants and the high cost of DAA treatments might limit the availability of these therapies worldwide [11] [12] [13] . The usefulness of DAA-based therapies for some patients-such as those with advanced infection, who are at the highest risk for hepatic decompensation, liver failure, hepatocellular carcinoma and/or death-also remains to be fully proven 13 . Hence, it is critical to identify the mechanisms that HCV employs which lead to the failure of type I IFN therapy. In this study, we show that HCV dampens type I IFN signaling by targeting IFNAR1 mRNA expression. This novel mechanism not only provides insight into why IFN-based HCV therapies have failed but also suggests why the interferon lambda 3 (IFNL3) genotype correlates with the outcome of type I IFN treatment.
Several viral and host factors are predictive of HCV clearance, including viral genotype, baseline viral load and host genotype. Genome-wide association studies have identified three singlenucleotide polymorphisms (SNPs) near the antiviral IFNL3 gene that associate with natural clearance of HCV 14, 15 and patient response to therapy 14, [16] [17] [18] . Ensuing studies have since identified four genetic variants in linkage disequilibrium with the primary tag SNPs [19] [20] [21] . One of these variants, rs368234815, is a dinucleotide frameshift variant that creates IFNL4, a gene upstream of IFNL3 (ref. 22) . Paradoxically, expression of IFNL4 correlates with viral persistence. The mechanism behind this correlation has yet to be fully elucidated. We identified rs4803217, located in the 3′ untranslated region (3′ UTR) of IFNL3, as a functional SNP that determines HCV clearance by altering IFNL3 expression 4 . We further showed that the protective allele (G/G, rs4803217) increases expression of IFNL3 by escaping both AU-rich element-mediated decay and post-transcriptional regulation by HCV-induced miRNAs, miR-208b and miR-499a-5p. IFNλ3 is a Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling l e t t e r s 1 4 7 6 VOLUME 22 | NUMBER 12 | DECEMBER 2016 nature medicine potent antiviral cytokine that induces expression of interferon-stimulated genes (ISGs). A recent study using ex vivo HCV-infected primary human hepatocytes demonstrated that the favorable IFNL3 genotype correlates with high ISG expression and subsequent antiviral activity in HCV-infected and adjacent cells 23 . In contrast, the magnitude of ISG expression in HCV-infected livers before IFN therapy has been shown to negatively correlate with response to pegIFN-α therapy 24 . This disparity underlines the complexity of IFN signaling in HCV infection, as well as how much remains to be understood about the interplay between virus, host and IFN therapies. Beyond its ability to predict natural clearance of HCV, IFNL3 genotype is also the strongest predictor of patient response to pegIFN-α plus ribavirin therapy: patients with the unfavorable allele are less likely to respond to this therapy than those with the favorable allele 14, [16] [17] [18] . This association between IFNL3 genotype and response to pegIFN-α therapy suggests a possible crossregulation of these pathways during infection, yet the mechanisms guiding this are unknown.
Factors have been identified within the type I IFN signaling pathway that correlate with the success of pegIFN-α and ribavirin therapy, among them the expression of IFNAR1 in the liver 25, 26 . IFNAR1 is a subunit of the type I IFN receptor composed of IFNAR1 and IFNAR2 chains. Studies have found that patients with high hepatic IFNAR1 mRNA responded better to IFN therapy, whereas patients who relapsed or did not respond to IFN therapy had intermediate or low hepatic IFNAR1 mRNA, respectively [27] [28] [29] [30] [31] subgenomic replicon induces the unfolded protein or endoplasmic reticulum stress response in hepatoma cells that indirectly decreases IFNAR1 protein levels 32, 33 . While these data provide insight into one mechanism regulating IFNAR1 surface expression during HCV infection, a mechanism that explains decreased IFNAR1 mRNA levels in HCV infected patients has yet to be described. Moreover, no study has indicated a HCV-specific factor that directly reduces IFNAR1 expression. miRNAs regulate gene expression by guiding mRNA degradation machinery to complementary sequences in the 3′ UTR of mRNAs 34 . We previously demonstrated that HCV infection induces expression of miR-208b and miR-499a-5p (ref. 4), two miRNAs not normally expressed in the liver. We hypothesized that within innate immune signaling pathways these miRNAs may target multiple genes in addition to IFNL2 and IFNL3. miR-208b and miR-499a-5p are termed "myomiRs" as they are encoded in the introns of two myosin-encoding genes, myosin heavy chain 7 (MYH7) and myosin heavy chain 7B (MYH7B), respectively 35 . Studies of miR-208b and miR-499a-5p in myofibers have shown that expression of these myomiRs correlates with expression of their respective parental genes MYH7 and MYH7B 35 . We found a significant correlation between transcript levels of MYH7 and MYH7B with their intronic pri-miRNAs and mature miRNAs in liver biopsies from patients chronically infected with HCV. This demonstrates that MYH7 and MYH7B expression can be used as a surrogate readout for myomiR expression 4 . Since HCV clearance depends on the host response to endogenous type I IFNs and/or therapeutic pegIFN-α, we were interested in determining whether these myomiRs targeted effectors in the type I IFN signaling pathway.
To investigate the effects of HCV-induced myomiRs on type I IFN signaling, we used previously characterized locked nucleic acid (LNA) inhibitors to inhibit endogenous miR-208b and miR-499a-5p during HCV infection of the hepatoma cell line Huh7 (ref. 4) . A LNA inhibitor with a non-targeting sequence that does not bind to any known miRNA was used as a non-targeting control (NC). Huh7 cells were transfected with myomiR inhibitors or an NC inhibitor, infected with HCV, and then treated with IFN-β. Exogenous IFN-β was used to mimic therapeutic and paracrine type I IFN signaling, as HCV disrupts signaling downstream of the helicase RIG-I (retinoic-acid-inducible gene), an essential pathogen-recognition receptor important for IFN induction. We confirmed that miR-208b, miR-499a-5p and their parental myosin genes were induced following infection as documented in our previous study 4 ( Fig. 1a, Supplementary Fig. 1a) . As expected, expression of the ISGs Mx GTPase (encoded by MX1), 2′-5′ oligoadenylate synthetase (OAS1) and the translational inhibitor PKR were all induced following IFN-β stimulation (Fig. 1b) . Interestingly, induction of these ISGs was significantly higher in cells treated with the myomiR inhibitors compared to the non-targeting control. Increased ISG expression in myomiR inhibitor-transfected cells correlated with decreases in viral titer and RNA copy number (Fig. 1c) . The effect of the inhibitors was dependent on HCV infection and IFN-β treatment, as there was no difference in ISG expression in either HCV-infected cells treated with inhibitors or mock-infected cells treated with IFN-β (Supplementary Fig. 1b,c) . In this system, type III IFNs had no measurable effect, and the difference seen in ISG expression was downstream of type I IFN in the presence of myomiRs ( Supplementary Text 1; Supplementary Fig. 2a-e) . Together these findings suggested that myomiR-regulated factor(s) influenced hepatocyte responsiveness to IFN-β and, importantly, that myomiR inhibition improved the anti-HCV response. As our data revealed that myomiR inhibition increased expression of multiple antiviral ISGs during HCV infection, we hypothesized that myomiRs may target an upstream effector in the type I IFN pathway. Given that reduced IFNAR1 mRNA has been reported in HCVinfected livers 27-31 , we investigated whether IFNAR1 mRNA could be targeted by these myomiRs. Computational analysis revealed that the IFNAR1 3′ UTR harbors multiple predicted miRNA recognition elements (MREs) for both miR-208b and miR-499a-5p (Fig. 1d,e) . This suggests that these myomiRs may regulate IFNAR1. To explore this further, we transfected myomiR inhibitors or an NC inhibitor into HCV-infected Huh7 cells. We discovered that myomiR-inhibitor-transfected cells had significantly higher IFNAR1 mRNA and cell surface expression than NC-transfected cells (Fig. 1f,g ). In contrast, expression of IFNAR2, which does not harbor MREs for the myomiRs in its 3′ UTR, was unaffected by the myomiR inhibitors (Fig. 1f) . This demonstrated that the HCV-induced myomiRs, miR-208b and miR-499a-5p, specifically reduced expression of the IFNAR1 subunit. In a pattern similar to that seen in HCV infection (Fig. 1b) , cells transfected with the myomiR mimics also showed and reduced pSTAT1 and ISG induction compared to control mimic-treated cells (Supplementary Text 2, Fig. 2a-e) . To confirm IFNAR1 targeting by miR-208b and miR-499a-5p, we used a firefly luciferase reporter assay where we cloned the human IFNAR1 3′ UTR downstream of the firefly luciferase gene. We observed decreased luciferase expression when the IFNAR1 3′ UTR luciferase construct was transfected into HepG2 cells overexpressing miR-208b or miR-499a-5p (Supplementary Fig. 1f) . Taken together, these observations reveal that miR-208b and miR-499a-5p antagonized type I IFN signaling by destabilizing and down-regulating IFNAR1, leading to dampened ISG expression.
As myomiRs targeted components of the type I and type III IFN pathways, which are central to the antiviral response against HCV, we reasoned that understanding myomiR induction and regulation could lead to the discovery of new antiviral targets. As there is a strong correlation between expression of miR-208b and miR-499a-5p with their parental genes, we used expression of MYH7 and MYH7B as surrogate readouts for myomiR expression in the current study.
We previously showed that MYH7 and MYH7B are not induced in Huh7 cells during infection with West Nile virus or Sendai virus, nor are they induced following stimulation with the HCV 3′ UTR PAMP or poly(I:C) 4 . In addition, we did not observe myosin expression in Dengue virus-infected Huh7 cells (Supplementary Fig. 3b) . Thus, all data to date suggest that myomiR/myosin induction is specific to HCV infection. We have also observed that MYH7 and MYH7B expression in JFH1 HCV-infected Huh7 cells correlated with the multiplicity of infection (MOI) (Fig. 3a) . Interestingly, treatment of HCV-infected Huh7 cells with a 2′-C-methyladenosine nucleoside analog inhibitor of HCV RNA-dependent RNA polymerase (NS5B) that blocks viral genome replication and reduces viral load 36,37 also blocked MYH7 and MYH7B induction in a dose-dependent fashion (Fig. 3b) . Using the HCV replicon system, we also observed that viral replication in the absence of viral entry was sufficient to induce myosin expression (Supplementary Text 3, Fig. 3c,d ). These data suggested that myosin expression was dependent on viral replication.
As type I and type III IFNs inhibit HCV replication, we reasoned that IFN treatment would also reduce myosin expression. Like NS5B inhibitor treatment, prolonged type I IFN treatment of HCVinfected Huh7 cells reduced viral titer and copy number ( Fig. 4a-c; MYH7B mRNA (fold) Fig. 3c) . However, treatment with either IFN-α or IFN-β dramatically increased MYH7 expression in HCV-infected cells compared to untreated infected cells, suggesting a role for type I IFNs in the regulation of MYH7 (Fig. 4a-c) . In line with this observation, type I IFN treatment of the Huh7 cell lines Huh7-K2040, Huh7-HP and Huh7-JFH1 that harbor HCV replicons also amplified MYH7 expression (Fig. 3c) . However, unlike type I IFNs, type III IFNs did not synergize with HCV to augment expression of myosin genes (Supplementary Text 4, Fig. 4a-d) . These data suggest that myomiRs connect the type I and III IFN pathways during HCV infection as type I IFNs can increase myomiRs, which consequently regulate type III IFN production and type I IFN signaling (Supplementary Text 5) .
Here we have shown that the HCV-induced myomiRs, miR-208b and miR-499a-5p, decrease IFNAR1 expression by destabilizing its mRNA transcript. miRNA repression of IFNAR1 was sufficient to decrease IFNAR1 surface expression and dampen the antiviral response to type I IFN. During HCV infection of hepatocytes, we observed that myomiR inhibitors rescued expression of IFNAR1 and amplified the antiviral response to type I IFN, resulting in decreased viral load. Based on these data and our previous observation that inhibition of myomiRs rescues expression of IFNL2 and the risk allele of IFNL3 during HCV infection, myomiR inhibition could aid in a multistep fashion by increasing both hepatocyte production of type III IFNs and responsiveness to pegIFN-α. This would be particularly relevant during IFN-based therapies, considering that we found that type I IFNs increase myosin/myomiR expression (Fig. 4) . The ability of type I IFNs to amplify myosin expression, a surrogate readout for myomiR expression, is also interesting in terms of type I IFN signaling feedback. myomiRs may function to blunt the cellular response to secondary type I IFN signaling, including the production of type III IFNs, which can be induced by prolonged type I IFN stimulation 38 (Supplementary Fig. 4) .
It is remarkable that unlike treatment with type I IFNs, treatment of HCV-infected hepatocytes with type III IFNs did not induce myosin/ myomiR expression, raising the possibility that type III IFN-based therapies will bypass IFN induction of these myomiRs. Currently, IFN-λ-based therapy is in phase 3 clinical trials, and results from phase 2 trials have shown it to be as effective as pegIFN-α with fewer adverse effects; this suggests that IFN-λ may be a viable replacement for pegIFN-α 39, 40 . myomiR inhibition may also benefit patients on IFN-free DAA regimens by increasing endogenous type III IFN production and type I IFN signaling. Taking these results together with our previous finding that these myomiRs also target IFNL2 and the risk variant of IFNL3, we conclude that myomiRs suppress both type I and type III IFN signaling during HCV infection. Collectively, these data add to our understanding of HCV immune evasion strategies and cross-talk between type I and type III IFN signaling pathways.
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